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Inflammatory myopathy (IM) 
is an umbrella term for a group 
of muscle diseases exemplified 
by dermatomyositis (DM) and 
polymyositis (PM). Collectively, 
these conditions were considered to be rare, but 
seem to be more common than previously 
thought. Making an incorrect diagnosis may 
be costly, as delays in initiating treatment may 
result in morbidity and mortality. As a disease 
entity IM is generally poorly understood 
compared with other connective tissue diseases 
(CTDs).[1,2] 
Diagnosis
The Bohan and Peter criteria[3,4] for diagnosing 
IM are listed below. Initially published in 
1975, these are still commonly referred to but 
have limited usefulness in clinical practice: 
• Symmetric proximal muscle weakness.
• Elevated serum muscle enzymes.
• Myopathic changes on electromyography 
(EMG).
• Typical cutaneous manifestations of DM (the 
clinical feature distinguishing DM from PM).
• Characteristic muscle biopsy abnormalities 
and the absence of histopathological signs 
of other muscle diseases.
Classification
Current classifications of IM are fraught with 
problems.[5] From a rheumatologist’s point of 
view it may be prudent to view IMs as being 
associated with a CTD or having a definite 
auto-immune aetiology. Therefore, inclusion 
body myositis (IBM) would probably not 
find a place in this sub-classification. A 
useful classification of IM is the following:
1. DM.
2. PM.
3.  DM and PM overlapping with a CTD, 
such as systemic lupus erythematosus 
(SLE)/scleroderma.
4.  Points 1 - 3 have another cause, such as 
malignancy or HIV.
5.  ‘Undifferentiated’ IM, such as necrotising auto-
immune inflammatory myopathy (NAM).
1. Dermatomyositis
The diagnosis of DM is generally based on 
the features of proximal muscle weakness 
of gradual onset, raised muscle enzymes, 
e.g. creatinine kinase (CK), and cutaneous 
features. The skin manifesta tions of DM may 
range from highly typical to subtle.[6]
Pathognomonic features are the heliotropic 
rash and Gottron’s lesions. The heliotropic rash 
(Fig. 1) is characterised by peri-orbital swelling 
and violaceous discoloration. This may be 
very severe and conspicuous, or subtle and 
transient, and may have disappeared when 
the patient presents with weakness. Gottron’s 
lesions (Fig. 2) are violaceous papules or 
scaly plaques on the extensor surfaces of the 
fingers, e.g. the knuckles.
Very suspicious features include well-
defined areas of erythematous swelling in a 
typical distribution, resulting in the V (Fig. 3) 
and shawl (Fig. 4) signs.
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Fig. 1. Heliotropic rash.
Fig. 2. Gottron’s lesions.
Fig. 3. The V sign.
CONTINUING MEDICAL EDUCATION
       December 2015, Vol. 105, No. 12
Less specific, but not uncommon skin 
manifestations include poikiloderma, 
seborrhoeic dermatitis/psoriasiform changes 
of the scalp and diffuse erythroderma. 
Amyopathic DM is a variant of DM that 
spares muscle and does not present with 
weakness, but may manifest with weakness 
in the course of the disease. The diagnosis is 
made on the findings of diagnostic cutaneous 
signs, such as the heliotropic rash referred to 
above.
In cases where the cutaneous signs are not 
convincing, a skin biopsy may be performed. 
The finding of an interface dermatitis is 
fairly specific for DM but also occurs in SLE.
2. Polymyositis
PM lacks the skin characteristics of DM but 
is suspected if there are other features of a 
CTD.[6] These include Raynaud’s phenomenon, 
peri-ungual swelling or erythema, ‘raggedy’ 
cuticles or other features of the antisynthetase 
syndrome. This syndrome refers to a patient 
with PM or DM with the typical findings 
of constitutional symptoms such as fever, 
polyarthritis, mechanic’s hands (Fig. 5), 
interstitial lung disease and the presence of 
anti-Jo-1 antibody in the serum.
The diagnosis of PM is more challenging 
because of the paucity of cutaneous clues. 
PM is currently considered a rare cause of 
IM. Previously, the diagnosis was largely 
clinical and the condition was probably over-
diagnosed. In retrospect, in many patients 
labelled as having PM, there were other 
causes for the proximal weakness, such as 
those mentioned in the differential diagnosis 
below.[7] 
When taking a history, the astute physician 
should look for clues, such as Raynaud’s 
phenomenon and inflammatory pain 
affecting the joints. On examination, one 
should look for other features of a CTD, such 
as abnormal capillaroscopy, puffy hands and 
interstitial lung disease. A dermatoscope, 
if available, is a preferred alternative to 
an ophthalmoscope to identify vascular 
abnormalities such as tortuosity and loss of 
capillaries in the nail bed. Occasionally, the 
diagnosis may lean heavily on the absence of 
another cause of the myopathy.
3. Inflammatory myopathy partially 
overlapping with another connective 
tissue disease
DM or PM may overlap with a CTD 
such as SLE, scleroderma or mixed CTD. 
However, deciding whether the IM is part 
of the underlying CTD and not necessarily 
overlapping with the IM may be difficult.
4. Inflammatory myopathy with 
underlying malignancy or HIV 
It is well known that DM (up to 15%) and to 
a lesser extent PM are often associated with 
an underlying malignancy such as carcinoma 
of the breast or lung. IM associated with HIV 
is discussed below.
5. ‘Undifferentiated inflammatory 
myopathy’, e.g. necrotising auto-immune 
myopathy (discussed below)
Differential diagnosis
Reviews of the histopathology of patients 
clinically diagnosed with IM not infrequently 
result in an alternative diagnosis.[8] These 
include:
• Inclusion body myositis
Some clinicians, in particular neurologists, 
include IBM as a subtype of IM, but 
the underlying aetiopathogenesis is a 
degenerative muscle disorder with little 
underlying inflammation, akin to an 
‘Alzheimer’s’ of muscle. It is characterised 
by slow onset of action, characteristically 
over many years, and atypical features such 
as distal muscle weakness, asymmetrical 
involvement, muscle atrophy and a poor 
response to steroids. The condition was 
previously regarded as exceedingly rare, 
but may be more common as retrospective 
reviews have uncovered many cases 
originally diagnosed as PM. It is also a rare 
cause of myopathy in individuals with HIV.
• Endocrine/electrolyte disorders
It is important to exclude hyper- and 
hypothyroidism. The latter, apart from 
causing proximal weakness, may also cause 
elevation of the serum CK. In the realm of 
the ‘metabolic’ myopathies, it is important 
to rule out hypokalaemia, hypo- and hyper-
calcaemia, osteomalacia and Cushing’s syn-
drome.
• Adverse effects of medication
Steroid-induced myopathy has to be consi-
dered in patients on maintenance oral 
steroids, e.g. those with poorly controlled 
asthma. Muscle weakness may occur in 
the absence of other features of Cushing’s 
syndrome. 
Although myalgia is a common symptom 
associated with the use of statins, weakness 
is rare. The mechanism is poorly understood 
but may be due to dose-related direct muscle 
toxicity and may very rarely be immune 
mediated[9] (discussed below). 
Colchicine may cause the feared side-
effect of a myoneuropathy, which may be 
irreversible. Patients particularly at risk 
of this rare complication are those with 
underlying renal impairment and the 
concomitant use of a macrolide antibiotic, 
e.g. clarithromycin.
Chloroquine is frequently used in 
rheumatic diseases such as rheumatoid 
arthritis and SLE, but fortunately the 
myopathy associated with its use is very rare.
Zidovudine is a well-known cause of 
HIV-associated muscle weakness owing to a 
mitochondrial myopathy.
• Diseases with pathology arising from 
the neuromuscular junction
Myasthenia gravis is a rare condition always 
worth considering, as the clues such as facial 
muscle weakness, ptosis and fatiguability 
may not always be obvious. 
The Lambert-Eaton myasthenic syndrome 
is a disorder occurring in the setting of an 
underlying malignancy such as bronchus 
carcinoma. 
• Muscle dystrophies
Limb girdle dystrophy. A family history and 
muscle atrophy involving the shoulder and 
pelvic girdle may be important clues. 
Myotonic dystrophy. This is characterised 
by myotonia and additional findings of a 
family history, cataracts, cognitive impair-
ment and impaired glucose tolerance.
• Metabolic myopathies 
These conditions usually have a hereditary 
component and noteworthy features are 
episodes of acute myalgia with associated 
myoglobinuria and accompanying dark-
coloured urine.
Atypical features that should 
suggest alternative diagnoses 
Severe muscle pain. Myalgia occurs in half 
of patients with an IM and is generally not a 
prominent feature. Severe pain suggests an 
Fig. 4. The shawl sign.
Fig. 5. Mechanic’s hands.
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infection or a metabolic cause. Pain mimics weakness, e.g. a typical 
patient with polymyalgia rheumatica may have shoulder girdle pain 
but present with ‘weakness’ rather than pain.
Acute onset. This should raise suspicion of an infective cause.
Normal or only slightly raised muscle enzymes. Although occa-
sionally found in IM, this is unusual.
Constitutional symptoms such as fever and weight loss. These 
occur more frequently in patients whose IM partially overlaps with 
another CTD such as SLE. If present, this should also prompt a search 
for an underlying malignancy or HIV.
Wasting, asymmetrical weakness and disproportionate distal 
weakness. These suggest a neurological cause such as motor neuron 
disease or IBM.
Global areflexia. This should raise suspicion of chronic demye-
linating polyneuropathy, which may uncommonly present with prox-
imal rather than distal weakness.
Myopathies due to HIV and NAM
These diseases may cause IM, but are worthwhile highlighting as they 
may cause weakness via other mechanisms. 
HIV may cause a clinical picture indistinguishable from PM 
clinically and histologically, usually occurs relatively early in the 
disease, and usually responds well to steroids. HIV may also cause 
muscle weakness on the basis of ‘non-immune’ mechanisms.[10-12] The 
nucleotide reverse transcriptase inhibitors may cause a mitochondrial 
myopathy with the diagnostic ragged red fibres on muscle histology. 
The chronic HIV wasting syndrome is the most common cause 
of muscle weakness in this illness and occurs in the late stages of 
the disease – it is usually not amenable to immunosuppressive 
therapy. IBM is a rare disease and may also occur in the setting of 
HIV. Myasthenia gravis and NAM (discussed below) are other rare 
illnesses linked to HIV.
NAM is a rare but important cause of myopathy.[13,14] It is 
associated with (i) CTDs such as SLE, scleroderma and mixed CTD; 
(ii) malignancy, such as carcinoma of the bronchus; (iii) statin use, 
although the myopathy caused by statins is generally via direct 
muscle toxicity and not immune mediated; and (iv) HIV or other 
viral infections. Knowledge about this condition is important as it 
requires treatment with immunosuppressive therapy such as that 
conventionally used for the treatment of IM. Anti-signal recognition 
particle antibody is a myositis-specific antibody associated with 
NAM, but is generally only used in research settings.
Appropriate investigations
With regard to the involvement of organ systems other than muscle 
and skin it is worthwhile trying to identify interstitial lung disease as 
it is reasonably common – in some studies affecting >50% of patients 
with IM. Cardiac involvement is rare. 
Serological tests. The antinuclear factor test is useful as a screening 
test to detect underlying CTD. The anti-Jo-1 antibody test, although 
not sensitive, is relatively specific for interstitial lung disease and the 
antisynthetase syndrome mentioned above. Myositis-specific anti-
bodies other than anti-Jo-1 have a very small role in current clinical 
practice. 
Magnetic resonance imaging (MRI). MRI of muscle may help to 
distinguish between active inflammation and muscle necrosis, but its 
future role is unclear.
EMG. This is reserved for patients where there is doubt about the 
presence of active muscle necrosis, such as those with a normal or 
slightly raised CK.
Histopathology. Although there are characteristic differences in 
the pattern of the inflammatory infiltrate between DM and PM, a 
muscle biopsy for histology is not routine practice. A more compelling 
indication for muscle biopsy is to shed light on the diagnosis of patients 
who cannot be confidently diagnosed as having IM. A muscle biopsy 
is an invasive procedure and it may be prudent to subject likely cases 
to a trial of immunosuppressive therapy, with a satisfactory response to 
therapy supporting the diagnosis of IM. Advocates of improved access 
to muscle histopathology feel that this will result in more accurate 
diagnoses and better decisions with regard to therapy.[15]
Conclusion
IM, although uncommon, is an important cause of myopathy, 
which should always be considered in the differential diagnosis of a 
patient who presents with proximal weakness. The clinical context, 
particularly the possible presence of CTD or other systemic illnesses, 
is an important guide to the diagnosis. 
Summary 
• IM should always be considered in a patient who presents with 
proximal weakness of gradual onset.
• In the absence of obvious skin manifestations, other features of 
CTDs such as Raynaud’s phenomenon, abnormal capilloroscopy 
and the presence of serum antinuclear factor antibody should be 
searched for. 
• Atypical features suggesting an alternative diagnosis are acute 
onset, severe pain, assymmetrical involvement, distal weakness, 
areflexia and wasting.
• EMG is useful to distinguish neurological from myopathic causes.
• Muscle biopsy is mandatory to distinguish between IM and other 
myopathies in the absence of obvious characteristic features.
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